Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05354947 · ClinicalTrials.gov registry record · NA
Ultrasound Effects on Glycemic Control in T2DM
A NA study of Type 2 Diabetes, sponsored by Yale University.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05354947: Recruiting NA study of Type 2 Diabetes, sponsored by Yale University.
NCT05354947 is a NA study of Type 2 Diabetes that is actively recruiting participants, run by Yale University. The registered enrollment target is 30 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05354947, a NA study of Type 2 Diabetes, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label, exploratory pilot study that will assess the effects of dual site focused pulsed ultrasound treatment on glycemic parameters in subjects with T2DM.
Primary Outcome
Number of study participants who develop an elevation of liver transaminases compared to baseline parameters, including AST and ALT. Grade 1 delta ALT and / or AST \<3 x ULN; Grade 2 delta ALT and / or AST \>3 - 5 x ULN; Grade 3 delta ALT and / or AST \>5 - 20 x ULN; Grade 4 delta ALT and / or AST \>20 x ULN.
Conditions Studied
Interventions
- DEVICE Ultrasound Delivery
Study Locations (1)
Connecticut
- Yale-New Haven Hospital - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-11-01 |
| Est. Completion | 2026-05 |
| Phase | NA |
What NCT05354947 shows while recruiting
NCT05354947 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Ultrasound Delivery is the first listed.
NCT05354947 reports a single indexed study location in Connecticut.
Frequently Asked Questions
What is clinical trial NCT05354947 about?
NCT05354947 is a clinical study titled "Ultrasound Effects on Glycemic Control in T2DM". This is an open label, exploratory pilot study that will assess the effects of dual site focused pulsed ultrasound treatment on glycemic parameters in subjects with T2DM.
What is the current status of trial NCT05354947?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2022-11-01. Estimated completion is 2026-05.
What conditions does trial NCT05354947 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT05354947?
The interventions under investigation include: Ultrasound Delivery (DEVICE).
Who is sponsoring clinical trial NCT05354947?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05354947 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05354947's enrollment target sits among peer trials
30 256th of 327 higher than 57 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
-
Black Impact: The Mechanisms Underlying Psychosocial Stress Reduction in a Cardiovascular Health Intervention
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI